


Background

- Methylphenidate (MPH) is a drug with a short duration of effect used in the treatment of ADHD in children, adolescents, and adults
- Extended-release (ER) products with different release profiles over the dose interval have been developed to eliminate the need for dosing during the school or working day
- Concerta[®] is *controlled*-release formulation



Objective



Johnson Johnson Pharmaceutical research & development, L.L.c.



Clinical Measures of ADHD

- SKAMP-Composite
 - A composite score from the Swanson, Kotkin, Agler, M-Flynn and Pelham Rating Scale
 - SKAMP-deportment & SKAMP-attention components
 - A validated classroom assessment tool used to evaluate the behavioral symptoms of ADHD in children in repeated fashion over a specified period of time
 - Smaller SKAMP-Composite scores indicate behavioral improvement



• PERMP

- PERManent Product measures
- PERMP-Attempted: quantifies the rate of behavior within a defined period of time (accurate measure of productivity)
- PERMP-Correct: measures the *ability to learn* how to do math problems (not a precise measure)





A Daily Schedule During Laboratory Classroom Day

Study Hour*	Preparation	-0.75	0 (Dose)	1.5	3.0	4.5	6.0	7.5	9	12
Time		[6:45 am]	[7:30 am]	[9:00 am]	[10:30 ам]	[12:00 pm]	[1:30 pm]	[3:00 pm]	[4:30 pm]	[7:30 pm]
Vital signst		Х		Х	Х	Х	Х	Х	Х	Х
SKAMP deportment			Х	Х	Х	Х	Х	Х		Х
SKAMP attention			Х	Х	Х	Х	Х	Х		Х
PERMP Complete Barkley Scale (parent/	х		Х	х	х	Х	х	х		Х
guardian) Assess AEs	Х									

- A good well-controlled study setting
- 7 scores per study day
- Measurements at the same clock times per study day
 - Every 1.5 hours from 7:30 am
 - Sampling time error interval ± 15 minutes



Swanson et al. Pediatrics, 113:e206, 2004



Challenges in Model Building


- Combination of summary data from literature and individual data from J&J studies
 - Model-based meta-analysis
- Lack of trials with simultaneous PK and PD data collection
 - PK from adult
 - PD from pediatrics
- Lack of a disease progress model
 - To separate true drug effect from observed combined placebo & drug effects
- Various study designs
 - Titration to a desired effect in each subject, and administration of the individual optimal dose during the assessment days in some studies
 - Different treatments between assessment days





Individualized Dose I

An ADHD Study Design: Laboratory School (Study ABC)






Individualized Dose II

An ADHD Study Design: Laboratory School (COMACS Study)

TABLE 1. Dosage Stratification	
Previous MPH Daily Dose	Stratification Dose
Low dose ≤15 mg of IR MPH or ≤20 mg of ER MPH (eg, 5 mg	MCD 20 mg vs CON 18 mg vs PLA (dose level 1)
BID/TID or 20 mg of MPH SR) Medium dose	
>10 to ≤30 mg IR MPH or >20 to ≤40 mg of ER MPH (eg, 10 mg BID/TID or 40 mg of MPH SR)	MCD 40 mg vs CON 36 mg vs PLA (dose level 2)
High dose >30 mg IR MPH or >40 mg of ER MPH (to a maximum of 60 mg) (eg, 15 mg BID/TID or 60 mg of MPH SR)	MCD 60 mg vs CON 54 mg vs PLA (dose level 3)

- Subjects assigned to the dose closest to their previous dose & remained at the level for the study duration
- 3-way cross-over: placebo, Concerta[®], Metadate CD[®]
- 7 days in each treatment: assessment on the 7th days
- No wash-out period
- 184 subjects

Baseline is Different Depending on Treatment History



Other Study Designs

Treatment	Design	Data	٢
d-MPH 20 mg/	Patients were stabilized on Concerta 36-54 or d-	SKAMP-Composite; PERMP-	Τ
Placebo	MPH ^a 20-30. Then, 7 days of 20 mg d-MPH or	Attempted and PERMP-	
	placebo with assessment on the last of seven days.	Correct change from	
	2 period cross-over	baseline at 0, 0.5, 1, 2, 4, 6,	
		8 hrs	8
Concerta 36 mg/	Patients were stabilized on Concerta 36-54 or d-	SKAMP-Composite, PERMP-	
Concerta 54 mg/	MPH ^a 20-30 mg/day. Then, 5 treatment period cross	Attempted and PERMP-	
d-MPH 20 mg/ d-	over with assessments on day 7 of each period.	Correct change from	
MPH 30 mg/		baseline at 0, 0.5, 1, 2, 3, 4,	
Placebo		6, 8, 10, 11, 12 hrs	ł
Ritalin LA 20 mg/	Patients were stabilized on <u>10 mg BID MPH</u> and	SKAMP–Composite, PERMP	
Concerta 18 mg/	remained on this medication during the study	–Attempted, and PERMP-	
Concerta 36 mg/	except for 4 assessment days when they were	,4, 3, 2, 2, Correct at 0, 0.5, 1, 2	
Placebo	administered randomized treatments. There was a	6, 8 hrs can be derived from	
	washout day without medication before each	the presented data	
	assessment. 4 period cross-over.		1
d-MPH 20 mg/ d-	Patients were stabilized on Concerta 36-54 or d-	SKAMP–Composite, PERMP	
MPH 30 mg/	MPH ^a 20-30 mg/day. Then, 5 treatments 7 days	–Attempted, and PERMP-	
Concerta 36 mg/	each, assessments on day 7 of each treatment. 4	Correct change from	
Concerta 54 mg/	period cross-over	baseline at 0, 0.5, 1, 2, 3, 5,	
Placebo		7, 9, 10, 11, 12 hrs	
d-MPH 20 mg/	Patients were stabilized on MPH 20–40 mg/day.	SKAMP–Composite, PERMP	t
Placebo	Then, 5 days of randomized treatment, then 1 day	–Attempted, and PERMP-	
	washout, then assigned treatment and	Correct at 0, 1, 2, 4, 6, 8, 9,	
and almost	assessments. 2 period cross-over	10, 11, 12 hrs can be derived	
eutical research		from the presented data	1



PK & PD Data Used

- Four different PK profile formulations
 - Concerta[®], Metadate CD[®], Focalin XR[®](d-MPH), Ritalin LA[®]
- Nine PD study
 - 8 studies for model building
 - 1 study for external evaluation


ID		Source of Data		Available Treatments / Dose Levels					
	PD type	РК	PD	Placebo	Concerta	MCD	dMPH ^a	Ritalin LA	
1	raw score	PK1, PK6	PD3	0	18	20			
2	raw score	PK1, PK6	PD3	0	36	40			
3	raw score	РК6	PD3	0	54	60			
4	change from baseline	PK4	PD4	0			20		
5	change from baseline	РК4, РК6	PD5	0	36, 54		20, 30		
6	raw score	PK1, PK2	PD6	0	18, 36			20	
7	change from baseline	РК4, РК6	PD7	0	36, 54		20, 30		
8	raw score	PK4	PD8	0			20		
9	raw score	PK1	ABC	0	18				
10	raw score	PK1	ABC	0	36				
11	raw score	PK6	ABC	0	54				




No PK Model Building



- The PK model of each formulation was not built
- The published mean PK data were used as a driver in the PD model








DP – *PK* – PD modeling!


Some of the SKAMP Data Used



HARMACEUTICAL RESEARCH

& DEVELOPMENT, L.L.C.

Disease Progress (Placebo) Model



- Disease progress was described from the placebo data
- Inversed indirect response model with time varying coefficient

$$\frac{dB}{dt} = k_{in} - \alpha(t) \cdot k_{out} \cdot B$$

at S.S, $B_0 = \frac{k_{in}}{k_{out}}$
$$\frac{d(\frac{B}{B_0})}{dt} = k_{out} - \alpha(t) \cdot k_{out} \cdot \frac{B}{B_0}$$

Johnson Johnson ARMACEUTICAL RESEARC & DEVELOPMENT LLC $\begin{aligned} \frac{dA}{dt} &= k_{out} \cdot \{1 - \alpha(t) \cdot A\} & 0 < A \leq 1 \\ placebo \ score &= \ constant - B_0 \cdot A \\ Empirically, \ constant \ \Rightarrow B0 \\ placebo \ score &= B_0 \cdot (1 - A) \end{aligned}$





PK-PD Model

$$Effect = delta + \frac{E_{max} \cdot C}{EC_{50} + C} \qquad EC_{50} = EC_{50,start} \cdot (1 + \frac{E_t \cdot time^{\gamma}}{T_{50}^{\gamma} + time^{\gamma}})$$

- A simple Emax-type model
- delta: The score difference at baseline depending on the treatment between assessment days
- Tolerance on EC50:
 - as time passes, higher EC50 → more drug is needed to achieve the same effect

Score(t) = Placebo(t) – Effect(t)


$$Y = Score(t) + \frac{1}{\sqrt{n_{ik}}}\varepsilon_{ik} \quad \text{or} \quad Y = Score(t) - Score_{Baseline} + \frac{\sqrt{2}}{\sqrt{n_{ik}}}\varepsilon_{ik}$$

• Available PD data: raw scores or change from the baseline





Weighting in Meta-Analysis




Individual score $\bigstar \rightarrow Y_{ij}(t) = score(t) + \eta_i^{study} + \eta_{ij}^{subject} + \varepsilon_{ij}(t)$

Each arm has a different number of subjects: n ik

$$\begin{array}{l} \text{Mean score in an arm } \bullet \neq \bar{Y}_{ik}(t) = \frac{1}{n_{ik}} \sum_{arm_{ik}} Y_{ij}(t) \\ \text{our observation!!} \\ \text{Ahn \& French, JPKPD} \\ \text{2010, 37:179-201} \end{array} \qquad \approx score(t) + \eta_i^{study} + \frac{1}{\sqrt{n_{ik}}} \eta_{ik}^{arm} + \frac{1}{\sqrt{n_{ik}}} \delta_{ik} \\ \eta_{ik}^{arm} = \frac{1}{\sqrt{n_{ik}}} \sum_{(ij)} \eta_{ij}^{patient} \quad \text{and} \quad \delta_{ik}(t) = \frac{1}{\sqrt{n_{ik}}} \sum_{(ij)} \varepsilon_{ij}(t) \\ \eta_{ik}^{arm} \sim N(0, \omega_k^2) \qquad \qquad \delta_{ik}(t) \sim N(0, \sigma^2) \end{array}$$

15

Internal Evaluation



& DEVELOPMENT, L.L.C.


Blue: 90% interval of simulated scores

16

External Evaluation



B₀ missing





Closing Remarks

- The DP-*PK*-PD model allowed prediction of response in pediatrics with various PK profiles from adults
- Model-based meta-analysis is a useful tool to do "competitive landscaping" of compounds of interest
 - Go/no-Go decision
 - Decision of a study design (power calculation with n, study period, doses, etc.)





Data Sources

PΚ

- PK1: Meeting of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology April 13, 2010, BRIEFING INFORMATION Page 32
- PK2: Ritalin[®] LA label (file 21-284_Ritalin LA_prntlbl.pdf)
- PK4: Tuerck D, *et al*. Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. J Clin Pharmacol. 2007 Jan;47(1):64-9.
- PK6: Gonzalez MA, *et al*. Methylphenidate bioavailability from two extended-release formulations,Int. J Clinical Pharmacology Therapeutics 2002 40 (4): 175-184.

PD

- PD1: Study ABC, J&J
- PD2 (Study 007, J&J): Swanson J, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children, Clin. Pharmacol. Ther. 1999 Sep; 66(3):295-305.
- PD3: Swanson JM, *et al.* COMACS Study Group. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics. 2004 Mar; 113(3 Pt 1):e206-16.
- PD4: Brams M, et al. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
 : CNS Drugs. 2008;22(8):693-704.

- PD5: Muniz R, *et al.* Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attentiondeficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol. 2008 Jun;18(3):248-56.
- PD6: Lopez F, *et al.* Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs. 2003;5(8):545-55.
- PD7: Silva R, *et al.* Treatment of Children with Attention-Deficit/Hyperactivity Disorder: Results of a Randomized, Multicenter, Double-Blind, Crossover Study of Extended-Release Dexmethylphenidate and d,l-Methylphenidate and Placebo in a Laboratory Classroom Setting. Psychopharmacol Bull. 2008;41(1):19-33.
- PD8: Silva RR, *et al*. Efficacy and duration of effect of extendedrelease dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2006 Jun;16(3):239-51.
- PD9: Pelham WE, *et al*. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001 Jun;107(6):E105.





